BusinessPROVECTUS BIOPHARMACEUTICALS COMPLETES ENROLLMENT OF PHASE 1B TRIAL OF PV-10 IN COMBINATION WITH KEYTRUDA® IN PATIENTS WITH METASTATIC MELANOMABy Nasdaq OMXMay 7, 2018, 12:01 PM UTC
BusinessSTUDY OF T CELL MEDIATED IMMUNITY FROM COMBINATION OF PV-10 AND IMMUNE CHECKPOINT BLOCKADE IN MURINE MELANOMA MODELS PUBLISHED IN PLOS ONEBy Nasdaq OMXApr 30, 2018, 1:01 PM UTC
BusinessPROVECTUS BIOPHARMACEUTICALS AND PEDIATRIC ONCOLOGY EXPERIMENTAL THERAPEUTICS INVESTIGATORS' CONSORTIUM (POETIC) ANNOUNCE ACCEPTANCE OF PV-10 POSTER PRESENTATION AT AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETINGBy Nasdaq OMXApr 25, 2018, 8:00 PM UTC
BusinessPROVECTUS BIOPHARMACEUTICALS ANNOUNCES CHANGES TO BOARD OF DIRECTORSBy Nasdaq OMXApr 24, 2018, 11:00 AM UTC
BusinessSECOND STUDY OF EXPANDED ACCESS PATIENTS TREATED WITH PV-10 FOR IN-TRANSIT MELANOMA PUBLISHED IN JOURNAL OF SURGICAL ONCOLOGYBy Nasdaq OMXApr 19, 2018, 10:00 AM UTC
BusinessPROVECTUS BIOPHARMACEUTICALS EXPANDS GLOBAL PATENT PORTFOLIO FOR CANCER COMBINATION THERAPYBy Nasdaq OMXApr 18, 2018, 10:00 AM UTC
BusinessPROVECTUS BIOPHARMACEUTICALS PROVIDES UPDATE ON GI CANCER PROGRAM FOR INVESTIGATIONAL DRUG PV-10By Nasdaq OMXFeb 22, 2018, 12:01 PM UTC
BusinessPROVECTUS BIOPHARMACEUTICALS RECEIVES THIRD CANCER COMBINATION THERAPY PATENT FROM THE UNITED STATES PATENT AND TRADEMARK OFFICEBy Nasdaq OMXDec 14, 2017, 11:00 AM UTC
